Could a single infusion of 'Trainer' cells let kidney patients ditch daily pills?

NCT ID NCT06777719

Recruiting now Disease control Sponsor: Nantes University Hospital Source: ClinicalTrials.gov ↗

First seen Jun 27, 2026 · Last updated Jun 27, 2026

Summary

This early-stage trial tests a new cell therapy called Eight Treg in 9 people receiving a kidney from a living donor. The therapy uses the patient's own immune cells, grown in a lab, to help the body accept the new kidney without strong anti-rejection drugs. The main goal is to check safety, but researchers hope it may one day reduce the need for lifelong medication.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: CD8+ regulatory T cells (Eight Treg)
What this could lead to: If successful, this could reduce the need for lifelong immunosuppressive drugs after kidney transplant, lowering infection and cancer risks.
What could go wrong: This is a very early Phase 1 trial with only 9 people, focused on safety. The therapy may not work or could cause unexpected side effects.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for END-STAGE RENAL DISEASE are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

end stage renal failure

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

KIDNEY TRANSPLANTATION

Contacts and locations

Locations

CHU de Nantes
RECRUITING

Nantes, 44093, France

More trials for these conditions

Other studies related to the condition(s) this trial covers.